, Paris Cardiovascular Research Center (PARCC
,
, Université Paris Descartes
, INSERM U1016
, University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute
, 3P5 proteomics facility
Cardiotoxicity of cancer therapy, Cancer Invest, vol.17, issue.6, pp.408-430, 1999. ,
Cardiac side-effects of cancer chemotherapy, Int J Cardiol, vol.144, issue.1, pp.3-15, 2010. ,
Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue, Circulation, vol.133, issue.13, pp.1272-89, 2016. ,
Cancer drug may cause heart failure, BMJ, vol.321, issue.7256, p.259, 2000. ,
Cardio-oncology, Immuno-oncology, Onco-cardiology and Onco-immunology, Int J Cardiol, vol.223, pp.254-261, 2016. ,
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition, Nat Rev Cancer, vol.7, issue.6, pp.475-85, 2007. ,
Clinical translation of angiogenesis inhibitors, Nat Rev Cancer, vol.2, issue.10, pp.727-766, 2002. ,
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib, Lancet Lond Engl, vol.370, issue.9604, pp.2011-2020, 2007. ,
Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects, J Hypertens, vol.27, issue.12, pp.2297-309, 2009. ,
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression, J Clin Endocrinol Metab, vol.96, issue.10, pp.3087-94, 2011. ,
Mechanisms of adverse effects of anti-VEGF therapy for cancer, Br J Cancer, vol.96, issue.12, pp.1788-95, 2007. ,
Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer. OncoTargets Ther, vol.8, pp.2435-2477, 2015. ,
Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition, Arch Dermatol, vol.144, issue.11, pp.1525-1531, 2008. ,
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, vol.356, issue.2, pp.115-139, 2007. ,
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, Lancet Lond Engl, vol.368, issue.9544, pp.1329-1367, 2006. ,
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors, N Engl J Med, vol.364, issue.6, pp.501-514, 2011. ,
Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1, J Hypertens, vol.31, issue.3, pp.444-454, 2013. ,
Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib, J Natl Cancer Inst, 2011. ,
Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity, Sci Transl Med, vol.5, issue.187, pp.187-69, 2013. ,
Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation, vol.122, pp.1004-1020, 2010. ,
Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels, Hypertension, vol.56, issue.4, pp.675-81, 2010. ,
Progress on the cardiotoxicity of sunitinib: Prognostic significance, mechanism and protective therapies, Chem Biol Interact, 2016. ,
Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun? Hypertens Dallas Tex 1979, vol.56, pp.575-582, 2010. ,
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertens Dallas Tex 1979, vol.64, pp.1282-1291, 2014. ,
Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease ,
, , vol.57, pp.772-781, 1979.
Noninvasive imaging of cardiovascular injury related to the treatment of cancer, JACC Cardiovasc Imaging, 2014. ,
Multimodality Imaging in Cardiooncology, J Oncol, p.263950, 2015. ,
Nuclear imaging in detection and monitoring of cardiotoxicity, World J Radiol, vol.6, issue.7, pp.486-92, 2014. ,
Enhanced myocardial fluorodeoxyglucose uptake following Adriamycin-based therapy: Evidence of early chemotherapeutic cardiotoxicity?, World J Radiol, vol.4, issue.5, pp.220-223, 2012. ,
A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate, PloS One, vol.12, issue.1, p.169964, 2017. ,
Glucose metabolism and cardiac hypertrophy, Cardiovasc Res, vol.90, issue.2, pp.194-201, 2011. ,
A PKM2 signature in the failing heart, Biochem Biophys Res Commun, vol.459, issue.3, pp.430-436, 2015. ,
Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblasts, Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol, vol.14, issue.4-6, pp.285-92, 2004. ,
Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertens Dallas Tex 1979, vol.33, pp.954-60, 1999. ,
Increased ETA and ETB receptor contraction in the left internal mammary artery from patients with hypertension, J Hum Hypertens, vol.22, issue.3, pp.226-235, 2007. ,
Insulin and Ischemia Stimulate Glycolysis by Acting on the Same Targets Through Different and Opposing Signaling Pathways, J Mol Cell Cardiol, vol.34, issue.9, pp.1091-1098, 2002. ,
Influence of dietary state and insulin on myocardial, skeletal muscle and brain [ 18 F]-fluorodeoxyglucose kinetics in mice, EJNMMI Res, vol.1, issue.1, p.8, 2011. ,
Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction, J Nucl Med Off Publ Soc Nucl Med, 2001. ,
Uptake as a Surrogate Marker for Antecedent Ischemia, J Nucl Med, vol.49, issue.12, pp.1909-1920, 2008. ,
Ischemically compromised myocardium displays different time-courses of functional recovery: Correlation with morphological alterations? ResearchGate, vol.20, pp.290-298, 2001. ,
Assessment of Myocardial Viability in Patients with Heart Failure, J Nucl Med, vol.48, issue.7, pp.1135-1181, 2007. ,
Chronic Ischemic Left Ventricular Dysfunction, JACC Cardiovasc Imaging, vol.1, issue.4, pp.536-55, 2008. ,
Pathophysiology of Severe Ischemic Myocardial Injury, p.448, 1990. ,
Sunitinib malate (SU-11248) reduces tumour burden and lung metastasis in an intratibial human xenograft osteosarcoma mouse model, Am J Cancer Res, vol.5, issue.7, pp.2156-68, 2015. ,
Regulation of energy metabolism of the heart during acute increase in heart work, J Biol Chem, vol.273, issue.45, pp.29530-29539, 1998. ,
Quantitative PET imaging detects early metabolic remodeling in a mouse model of pressure-overload left ventricular hypertrophy in vivo, J Nucl Med Off Publ Soc Nucl Med, 2013. ,
, Imaging of Myocardial Metabolism. ResearchGate, pp.641-56, 2010.
Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer, Thyroid Off J Am Thyroid Assoc, 2011. ,
Effects of ischemia and reperfusion on pyruvate dehydrogenase activity in isolated rat hearts, J Mol Cell Cardiol, vol.15, issue.6, pp.359-67, 1983. ,
Heart and skeletal muscle glucose disposal in type 2 diabetic patients as determined by positron emission tomography, 1994. ,
Decreased myocardial glucose uptake during ischemia in diabetic swine, Metabolism, vol.46, issue.2, pp.168-72, 1997. ,
Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes, Expert Opin Investig Drugs, vol.25, issue.3, pp.287-96, 2016. ,
Endothelin-1 suppresses insulin-stimulated Akt phosphorylation and glucose uptake via GPCR kinase 2 in skeletal muscle cells, Br J Pharmacol, vol.173, issue.6, pp.1018-1050, 2016. ,
Regulation of Glucose Uptake by Endothelin-1 in Human Skeletal Muscle in Vivo and in Vitro, J Clin Endocrinol Metab, vol.95, issue.5, pp.2359-66, 2010. ,
Endothelin-1 Reduces Glucose Uptake in Human Skeletal Muscle In Vivo and In Vitro, Diabetes, vol.60, issue.8, pp.2061-2068, 2011. ,
The role of AMP-activated protein kinase in the cardiovascular system, Hypertens Res, vol.33, issue.1, pp.22-30, 2009. ,
The role of the sarcoplasmic reticulum in the response of ferret and rat heart muscle to acidosis, J Physiol, vol.384, pp.431-480, 1987. ,
Metabolic Reserve of the Heart: The Forgotten Link Between Contraction and Coronary Flow, Prog Cardiovasc Dis, vol.51, issue.1, pp.74-88, 2008. ,
Mechanism of the diastolic dysfunction induced by glycolytic inhibition. Does adenosine triphosphate derived from glycolysis play a favored role in cellular Ca2+ homeostasis in ferret myocardium?, J Clin Invest, vol.93, issue.3, pp.1216-1239, 1994. ,
Cardiac fibrosis as a cause of diastolic dysfunction, Herz, vol.27, issue.2, pp.92-100, 2002. ,
Diastolic heart failure, Cardiovasc Res, vol.45, issue.4, pp.813-838, 2000. ,
Role of endothelin in fibrosis and anti-fibrotic potential of bosentan, Ann Med, vol.37, issue.1, pp.2-12, 2005. ,
Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs; Evid-Based Complement Altern Med ECAM, 2013. ,
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res Off J Am Assoc Cancer Res, vol.9, issue.1, pp.327-364, 2003. ,
Impact of Image-Derived Input Function and Fit Time Intervals on Patlak Quantification of Myocardial Glucose Uptake in Mice, J Nucl Med Off Publ Soc Nucl Med, 2015. ,
Universal sample preparation method for proteome analysis, Nat Methods, vol.6, issue.5, pp.359-62, 2009. ,
Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips, Nat Protoc, vol.2, issue.8, pp.1896-906, 2007. ,
Minimal, encapsulated proteomicsample processing applied to copy-number estimation in eukaryotic cells, Nat Methods, vol.11, issue.3, pp.319-343, 2014. ,
Proteomic workflow for analysis of archival formalin-fixed and paraffin-embedded clinical samples ot a depth o f0 0100 proteins, Proteomics Clin Appl, vol.7, issue.3-4, pp.225-258, 2013. ,
A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics, Nat Protoc, vol.4, issue.5, pp.698-705, 2009. ,
A "proteomic ruler" for protein copy number and concentration estimation without spike-in standards, Mol Cell Proteomics MCP, vol.13, issue.12, pp.3497-506, 2014. ,
Comparative differential proteomic profiles of nonfailing and failing hearts after in vivo thoracic aortic constriction in mice overexpressing FKBP12.6, Physiol Rep, 2013. ,
2016 update of the PRIDE database and related tools, Nucleic Acids Res, vol.44, issue.D1, pp.447-456, 2016. ,